Breaking · FDA Approval
Eli Lilly's orforglipron, branded as Foundayo, received FDA approval on April 1 as the first daily pill for obesity treatment—a seismic shift for the 40 million Americans currently on injectable GLP-1 medications. The drug showed 7–9% weight loss in trials, less than injectable tirzepatide's 20%, but analysts say convenience could drive adoption past injectables within two years.
By The GLP Truth Staff · April 8, 2026 · 8 min read
FDA & Regulation
The agency declared semaglutide and tirzepatide shortages officially resolved, then moved swiftly against telehealth companies still marketing compounded versions. Patients on compounded medications face immediate supply disruption.
March 2026 · 6 min read
Market & Pricing
The Danish pharmaceutical giant announced its biggest-ever U.S. price reduction, bringing Wegovy's list price to approximately $675/month. The move comes as Medicare negotiates $274/month coverage under the Inflation Reduction Act, effective January 2027.
Feb 24, 2026 · CNBC · 5 min read
Clinical Science
A growing body of evidence shows rapid weight loss on semaglutide and tirzepatide comes at a hidden cost. New research in Obesity Reviews quantifies what physicians have warned about for years: without resistance training and protein protocols, patients are losing the tissue their metabolism depends on.
Featured Investigation · 12 min read
Clinical Trial
The long-awaited direct comparison showed tirzepatide producing 20.2% body weight loss versus 13.7% for semaglutide over 72 weeks. The dual GIP/GLP-1 mechanism appears to deliver meaningfully superior outcomes across every measured endpoint.
NEJM · 2026 · 7 min read
Regulation
At least six states have introduced legislation restricting 503A compounding pharmacies from producing GLP-1 receptor agonists. The legal landscape is shifting faster than most patients realize.
April 2026 · 4 min read
Insurance
The Inflation Reduction Act's anti-obesity medication provision takes effect, covering semaglutide at $274/month for Medicare Part D enrollees. CMS expects 3.4 million new prescriptions in the first year, with prior authorization requirements varying by plan.
CMS · March 2026 · 5 min read
Patient Safety
Severe appetite suppression reduces caloric intake by 30–40%—and micronutrient intake drops with it. Vitamin D, B12, magnesium, and potassium deficiencies are near-universal among long-term GLP-1 users. Only 20% receive dietitian referrals.
Investigation · 10 min read
Drug Pipeline
Eli Lilly's triple-receptor agonist (GIP + GLP-1 + glucagon) showed 24%+ weight loss in Phase 2—the highest of any obesity drug in history. Phase 3 enrollment is complete with results anticipated Q4 2026.
Eli Lilly · Pipeline Watch · 4 min read
